Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Alliance for Clinical Trials in Oncology
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06931340CT.gov Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | — | Recruiting | — | — | — |
NCT06592924CT.gov Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | — | Recruiting | — | — | — |
NCT05960578CT.gov Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | — | Active Not Recruiting | — | — | — |
NCT06067269CT.gov Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | — | Recruiting | — | — | — |
NCT05683964CT.gov Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | — | Active Not Recruiting | — | — | — |
NCT04530552CT.gov Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | — | Active Not Recruiting | — | — | — |
NCT03902951CT.gov Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04513717CT.gov Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | — | Active Not Recruiting | — | — | — |
NCT04423211CT.gov Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | — | Recruiting | — | — | — |
NCT04134260CT.gov Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | — | Recruiting | — | — | — |
Show 10 more trialsShow fewer
NCT03503344CT.gov Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03821792CT.gov Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03371719CT.gov Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial | — | Active Not Recruiting | — | — | — |
NCT03412396CT.gov Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | — | Active Not Recruiting | — | — | — |
NCT03360721CT.gov Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02721979CT.gov Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | — | Terminated | — | — | — |
NCT03279250CT.gov Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | — | Completed | — | — | — |
NCT02949284CT.gov Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | — | Active Not Recruiting | — | — | — |
NCT02849990CT.gov A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | — | Completed | — | — | — |
NCT02703623CT.gov Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apalutamide (this asset) | Alliance for Clinical Trials in Oncology | P3 | B · 62 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Prednisone | Mayo Clinic | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
| Lidocaine | Bagcilar Training and Research Hospital | P4 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Apalutamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BB · 67 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 67 |
| Prostate Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apalutamide in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apalutamide-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →